相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence
Sneha Ramakrishna et al.
CLINICAL CANCER RESEARCH (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
Chimeric antigen receptor-modified T cells: CD19 and the road beyond
Alexander I. Salter et al.
BLOOD (2018)
Protein kinase C: perfectly balanced
Alexandra C. Newton
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2018)
Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering
May Daher et al.
CURRENT OPINION IN IMMUNOLOGY (2018)
Bryostatin-1 alleviates experimental multiple sclerosis
Michael D. Kornberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
Protein kinase C as a tumor suppressor
Alexandra C. Newton
SEMINARS IN CANCER BIOLOGY (2018)
REDOR NMR Reveals Multiple Conformers for a Protein Kinase C Ligand in a Membrane Environment
Hao Yang et al.
ACS CENTRAL SCIENCE (2018)
Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
Karie Runcie et al.
MOLECULAR MEDICINE (2018)
Tumor Antigen Escape from CAR T-cell Therapy
Robbie G. Majzner et al.
CANCER DISCOVERY (2018)
Bryostatin Effects on Cognitive Function and PKCε in Alzheimer's Disease Phase IIa and Expanded Access Trials
Thomas J. Nelson et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Strategies and challenges for the next generation of antibody drug conjugates
Alain Beck et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV
Paul A. Wender et al.
SCIENCE (2017)
Molecular dynamics simulations reveal ligand-controlled positioning of a peripheral protein complex in membranes
Steven M. Ryckbosch et al.
NATURE COMMUNICATIONS (2017)
In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell kick and kill in strategy for virus eradication
Matthew D. Marsden et al.
PLOS PATHOGENS (2017)
Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation
Brice J. Albert et al.
SCIENTIFIC REPORTS (2017)
The Principles of Engineering Immune Cells to Treat Cancer
Wendell A. Lim et al.
CELL (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy
Carolina Gutierrez et al.
AIDS (2016)
Natural Products as Sources of New Drugs from 1981 to 2014
David J. Newman et al.
JOURNAL OF NATURAL PRODUCTS (2016)
Mechanisms of Resistance to Antibody-Drug Conjugates
Frank Loganzo et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Gain-of-function mutations in protein kinase Cα (PKCα) may promote synaptic defects in Alzheimer's disease
Stephanie I. Alfonso et al.
SCIENCE SIGNALING (2016)
Gain-of-function mutations in protein kinase Cα (PKCα) may promote synaptic defects in Alzheimer's disease
Stephanie I. Alfonso et al.
SCIENCE SIGNALING (2016)
Determination of the effect of target site density on the efficacy of CD22 chimeric antigen receptor t-cell therapy to treat acute lymphoblastic leukemia.
Sang Nguyen et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Function through Synthesis-Informed Design
Paul A. Wender et al.
ACCOUNTS OF CHEMICAL RESEARCH (2015)
Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations
Gregory M. Laird et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo
C. Korin Bullen et al.
NATURE MEDICINE (2014)
Bryostatin-1 Restores Hippocampal Synapses and Spatial Learning and Memory in Adult Fragile X Mice
Miao-Kun Sun et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Levels of Murine, but Not Human, CXCL13 Are Greatly Elevated in NOD-SCID Mice Bearing the AIDS-Associated Burkitt Lymphoma Cell Line, 2F7
Daniel P. Widney et al.
PLOS ONE (2013)
PKC Activation in Niemann Pick C1 Cells Restores Subcellular Cholesterol Transport
Farshad Tamari et al.
PLOS ONE (2013)
The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion
Viola Biberacher et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro
Brian A. DeChristopher et al.
NATURE CHEMISTRY (2012)
Design, synthesis, and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity
Paul A. Wender et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Protein kinase C: poised to signal
Alexandra C. Newton
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2010)
AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology?
Mercy Guech-Ongey et al.
BLOOD (2010)
Translating cancer research into targeted therapeutics
J. S. de Bono et al.
NATURE (2010)
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
Ji Luo et al.
CELL (2009)
Prolonging microtubule dysruption enhances the immunogenicity of chronic lymphocytic leukaemia cells
S. P. Shaha et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
Function-oriented synthesis, step economy, and drug design
Paul A. Wender et al.
ACCOUNTS OF CHEMICAL RESEARCH (2008)
Efficient synthetic access to a new family of highly potent bryostatin analogues via a prins-driven macrocyclization strategy
Paul A. Wender et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2008)
Effect of serum and antioxidants on the immunogenicity of protein kinase C-activated chronic lymphocytic leukemia cells
C Hammond et al.
JOURNAL OF IMMUNOTHERAPY (2005)
The life and times of ivermectin - a success story
S Omura et al.
NATURE REVIEWS MICROBIOLOGY (2004)
Aquaculture of three phyla of marine invertebrates to yield bioactive metabolites: process developments and economics
D Mendola
BIOMOLECULAR ENGINEERING (2003)
Bryostatin-1: A novel PKC inhibitor in clinical development
J Kortmansky et al.
CANCER INVESTIGATION (2003)
The practical synthesis of a novel and highly potent analogue of bryostatin
PA Wender et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2002)
Protein kinase C: Structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions
AC Newton
CHEMICAL REVIEWS (2001)
分享论文
